Therapeutic Advances in Neurological Disorders · 2012 · 672 citations · 46 references
MedicineNeurologyPharmacologyDementiaNeurodegenerationNeuropharmacologyAlzheimer DiseaseCholinergic PharmacologyDementia TreatmentEnzyme InhibitionNeurodegenerative DiseasesNeurodegenerative DisordersAlzheimer Disease DementiaAmyloid Beta PlaquesAmyloid PlaquesN-methyl-d-aspartate Receptor AntagonismN-methyl-d-aspartate Receptor InhibitionPharmacological Treatment Of DementiaSymptomatic PharmacotherapySymptomatic Therapy
Alzheimer’s disease is a major global health issue for older adults, currently treated only symptomatically with cholinesterase inhibitors and memantine, while disease‑modifying therapies targeting amyloid, tau, inflammation, and other pathogenic processes remain under active investigation. This review examines existing symptomatic therapies and evaluates emerging disease‑modifying treatments for Alzheimer’s disease in phase I–III clinical trials. The authors analyze and synthesize evidence from phase I–III trials on symptomatic and disease‑modifying interventions for Alzheimer’s disease.
Alzheimer’s dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as ‘disease-modifying’ drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. In this review we discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials.
46
Reisa A. Sperling, Paul Aisen, Laurel Beckett et al. · Alzheimer s & Dementia · 2011 · 7.1K citations · Full text
Medicine, Neurology, Neuroscience +17
Global prevalence of dementia: a Delphi consensus study
Cleusa P. Ferri, Martin Prince, Carol Brayne et al. · The Lancet · 2005 · 5.3K citations · Full text
Revising the definition of Alzheimer's disease: a new lexicon
Bruno Dubois, Howard Feldman, Claudia Jacova et al. · The Lancet Neurology · 2010 · 1.9K citations · Full text
Statins and the risk of dementia
Hershel Jick, GL Zornberg, Sudha Seshadri et al. · The Lancet · 2000 · 1.8K citations